Semler Scientific (SMLR) Competitors $42.53 +0.35 (+0.83%) As of 12:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SMLR vs. CNMD, AORT, CDRE, ESTA, TNDM, FNA, BLFS, LQDA, SSII, and PLSEShould you be buying Semler Scientific stock or one of its competitors? The main competitors of Semler Scientific include CONMED (CNMD), Artivion (AORT), Cadre (CDRE), Establishment Labs (ESTA), Tandem Diabetes Care (TNDM), Paragon 28 (FNA), BioLife Solutions (BLFS), Liquidia Technologies (LQDA), SS Innovations International (SSII), and Pulse Biosciences (PLSE). These companies are all part of the "medical equipment" industry. Semler Scientific vs. Its Competitors CONMED Artivion Cadre Establishment Labs Tandem Diabetes Care Paragon 28 BioLife Solutions Liquidia Technologies SS Innovations International Pulse Biosciences Semler Scientific (NASDAQ:SMLR) and CONMED (NYSE:CNMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation. Which has stronger valuation and earnings, SMLR or CNMD? CONMED has higher revenue and earnings than Semler Scientific. Semler Scientific is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSemler Scientific$56.29M10.35$40.90M-$2.61-16.31CONMED$1.31B1.17$132.42M$3.8012.98 Do analysts rate SMLR or CNMD? Semler Scientific currently has a consensus price target of $89.00, indicating a potential upside of 109.11%. CONMED has a consensus price target of $62.20, indicating a potential upside of 26.09%. Given Semler Scientific's stronger consensus rating and higher possible upside, research analysts clearly believe Semler Scientific is more favorable than CONMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Semler Scientific 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33CONMED 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media prefer SMLR or CNMD? In the previous week, Semler Scientific had 8 more articles in the media than CONMED. MarketBeat recorded 12 mentions for Semler Scientific and 4 mentions for CONMED. CONMED's average media sentiment score of 0.76 beat Semler Scientific's score of 0.51 indicating that CONMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Semler Scientific 1 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CONMED 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, SMLR or CNMD? Semler Scientific has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, CONMED has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Do institutionals & insiders believe in SMLR or CNMD? 49.4% of Semler Scientific shares are owned by institutional investors. 30.2% of Semler Scientific shares are owned by insiders. Comparatively, 3.1% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is SMLR or CNMD more profitable? CONMED has a net margin of 9.02% compared to Semler Scientific's net margin of -60.69%. Semler Scientific's return on equity of 19.75% beat CONMED's return on equity.Company Net Margins Return on Equity Return on Assets Semler Scientific-60.69% 19.75% 15.47% CONMED 9.02%14.36%5.86% SummarySemler Scientific beats CONMED on 11 of the 17 factors compared between the two stocks. Get Semler Scientific News Delivered to You Automatically Sign up to receive the latest news and ratings for SMLR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SMLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SMLR vs. The Competition Export to ExcelMetricSemler ScientificMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$586M$6.63B$5.56B$9.26BDividend YieldN/A1.20%4.23%4.03%P/E Ratio-16.4025.4028.5819.56Price / Sales10.3586.75434.47183.65Price / Cash10.1120.3636.0257.93Price / Book1.714.618.165.58Net Income$40.90M$174.76M$3.24B$257.82M7 Day Performance0.57%-1.81%-0.64%-0.39%1 Month Performance39.46%0.59%4.93%7.80%1 Year Performance21.05%1.78%26.04%12.95% Semler Scientific Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SMLRSemler Scientific2.5925 of 5 stars$42.56+0.9%$89.00+109.1%+21.4%$586M$56.29M-16.40120CNMDCONMED4.6933 of 5 stars$51.86-4.5%$62.20+19.9%-28.7%$1.68B$1.31B13.653,900News CoverageAORTArtivion2.3508 of 5 stars$30.22-1.6%$32.40+7.2%+12.9%$1.31B$388.54M-60.441,600CDRECadre2.9481 of 5 stars$31.84-1.2%$37.50+17.8%-14.5%$1.31B$567.56M33.522,284ESTAEstablishment Labs1.5289 of 5 stars$46.11+5.9%$52.40+13.6%-2.4%$1.26B$166.02M-14.871,018Analyst ForecastTNDMTandem Diabetes Care4.1794 of 5 stars$16.25-3.2%$33.43+105.7%-67.9%$1.12B$982.95M-5.852,650Positive NewsAnalyst RevisionFNAParagon 28N/A$13.11+0.1%$12.75-2.7%+70.9%$1.10B$256.18M-17.71343,000High Trading VolumeBLFSBioLife Solutions2.1527 of 5 stars$21.81-4.5%$31.17+42.9%-0.1%$1.08B$82.25M-75.20440Positive NewsLQDALiquidia Technologies3.1978 of 5 stars$12.45+2.1%$26.89+116.0%+16.6%$1.04B$14M-7.8850Trending NewsInsider TradeSSIISS Innovations InternationalN/A$5.27-1.3%N/AN/A$1.03B$20.65M0.004PLSEPulse Biosciences3.715 of 5 stars$15.81+3.3%$22.00+39.2%-22.0%$1.03B$700K0.00140 Related Companies and Tools Related Companies CONMED Alternatives Artivion Alternatives Cadre Alternatives Establishment Labs Alternatives Tandem Diabetes Care Alternatives Paragon 28 Alternatives BioLife Solutions Alternatives Liquidia Technologies Alternatives SS Innovations International Alternatives Pulse Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SMLR) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Semler Scientific Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Semler Scientific With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.